Compare Biogen Inc (BIIB) vs Bank of Montreal (BMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Bank of Montreal — how do they compare? Biogen Inc trades at $204.1 (market cap $30.60B), while Bank of Montreal trades at $182.04 (market cap $127.25B). The key difference: Bank of Montreal is far larger — about 4.2× Biogen Inc's market cap, and Bank of Montreal pays a 2.68% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | BMO | |
|---|---|---|
Market Cap | $30.60B | $127.25B |
Sector | Health | Financials |
52-Week High | $216.63 | $183.65 |
52-Week Low | $128.93 | $112.54 |
Enterprise Value | $37.67B | — |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.94, up 0.8% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $234.47. The company has beaten earnings estimates for three consecutive quarters, including Q2 2026 EPS of $3.60 versus $2.94 expected, and recently completed the acquisition of RayThera Inc. to bolster its immunology pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%.
The outlook is positive, driven by strong execution and growth from newer drugs like Leqembi, though risks include pressure on legacy multiple sclerosis sales and a high P/E ratio of 36.93. The stock offers potential upside to the analyst target but faces earnings volatility and integration risks from recent acquisitions.
BMO trades at $181.55, up 0.4% with a bullish technical signal. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $2.66. Recent strategic moves include the $1.44 billion sale of Moneris and the acquisition of Euroz Hartleys' Australian capital markets business, strengthening its global metals and mining franchise. The stock shows strong fundamental performance with 25.92% net income margin and 11.05% ROE.
BMO presents a balanced investment case with solid earnings momentum and strategic expansion, though trading near resistance at $182. Key opportunities include consistent dividend payments and global banking recognition, while risks involve interest rate sensitivity and competitive pressures in the North American banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →
